News by Tag: Dyslipidemia Market
Pfizer Doing its Every Bit to Save its Blockbuster From an Expected Free Fall
November 11, 2011
With billions of dollars at stake, Pfizer is doing its every bit to save Lipitor from a complete free-fall resulting from its patent expiry later this month.
November 11, 2011
With billions of dollars at stake, Pfizer is doing its every bit to save Lipitor from a complete free-fall resulting from its patent expiry later this month.
Despite an Increasing Volumes, the US Dyslipidemia Market to Decline by a CAGR of 10% during 2010-2016
September 26, 2011
A new report from IMARC Group expects the US dyslipidemia market to decrease by value in the coming years.
September 26, 2011
A new report from IMARC Group expects the US dyslipidemia market to decrease by value in the coming years.
Generics to account for more than 92% of the US Dyslipidemia market by 2016
August 22, 2011
A new report from IMARC Group expects the volume share of generic drugs in the US Dyslipidemia market to reach levels worth more than 92% by 2016.
August 22, 2011
A new report from IMARC Group expects the volume share of generic drugs in the US Dyslipidemia market to reach levels worth more than 92% by 2016.